<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623974</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0562</org_study_id>
    <nct_id>NCT00623974</nct_id>
  </id_info>
  <brief_title>Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia</brief_title>
  <official_title>A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared
      to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive
      neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck,
      mediastinal lymph node neck dissections), with which serum calcium will be raised to
      corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end
      of the treatment course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Teriparatide is designed to act like a natural human hormone called parathyroid hormone,
      which can increase the blood levels of calcium. Calcium plus calcitriol is considered the
      standard treatment for low calcium in the blood.

      After scheduled surgery, the level of calcium in the blood will be monitored according to the
      standard of care. Between 18 and 24 hours after the surgery, if calcium level drops below an
      acceptable level, or participants develop symptoms of low calcium, they will be randomly
      assigned (as in the toss of a coin) to 1 of 4 groups. One group (the &quot;standard-of-care&quot;
      group) will receive calcium plus calcitriol alone, for 7 days. The other groups (the
      &quot;teriparatide&quot; groups) will receive 1 of 3 different dose levels of teriparatide for 7 days,
      plus calcium and calcitriol for 7 days. There is an equal chance of getting assigned to any
      of these 4 groups, for the first 40 participants enrolled on this study. If enrolled after
      that point, participants will have a greater chance of being assigned to the group showing
      the best results.

      Standard-of-Care Group:

      If assigned to the standard-of-care group, participant will receive calcium and calcitriol
      according to the standard schedule and dose. The calcium will either be given through a vein
      or by mouth, and calcitriol will be given by mouth.

      Teriparatide Group:

      If assigned to a teriparatide group, participant will receive teriparatide by an injection
      under the skin, twice a day for 7 days. They will be taught how to perform the injections
      themselves, with a pen-sized device. While in the hospital, the hospital staff will watch
      them perform the injections and offer help, if needed. If discharged from the hospital and
      sent home before the 7 days of therapy are complete, they will continue giving themselves the
      injections (through Day 7) at home. The pen should not be removed from refrigeration for more
      than 2 -4 hours. Depending on what dose level of teriparatide assigned to receive, they may
      have to give themselves up to 3 injections each time. In addition to teriparatide, they will
      receive calcium and calcitriol, according to the standard schedule and dose. The calcium will
      either be given through a vein or by mouth, and calcitriol by mouth.

      Both Groups:

      If blood calcium level has not returned to normal after the 7 days of treatment, participants
      may need to continue receiving calcium and/or calcitriol for as long as the doctor decides it
      is necessary.

      They will be asked to keep a medication log (diary) of when they take the teriparatide and/or
      calcium/calcitriol. The log should be returned to the research nurse on Day 8.

      On Days 1-7, blood will be drawn to check the level of calcium twice a day (while in the
      hospital) or once a day (while treated as an outpatient). These blood draws (about 1 teaspoon
      each time) will be performed 2 hours before receiving teriparatide and/or calcium/calcitriol.

      Blood will also be drawn to check calcium and parathyroid hormone levels after the study
      treatment is over. The first of these blood draws (about 1 tablespoon each time) will be
      performed at 3 days after receiving last dose of teriparatide and/or last dose of
      calcium/calcitriol. The second blood draw will be performed at 4 weeks after the surgery.

      Starting on Day 7, and again at 4 weeks after surgery, they will be asked to collect urine
      over the course of a 24-hour period so calcium levels can be measured.

      From Day 1 to Day 7, if discharged from the hospital and sent home, the study personnel will
      call on the phone once a day to see how participants are doing. At 3 days after receiving the
      last dose of teriparatide and/or the last dose of calcium/calcitriol, and at 4 weeks after
      the surgery, they will be called again.

      After the urine collection, blood draw, and phone call at 4 weeks after the surgery,
      participation in the study is over.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Success</measure>
    <time_frame>2 - 7 days post-treatment</time_frame>
    <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypocalcemia</condition>
  <arm_group>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide (Forteo)</intervention_name>
    <description>Subcutaneous Injection Every 12 Hours for 7 Days</description>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <other_name>Forteo</other_name>
    <other_name>PTH</other_name>
    <other_name>Parathyroid Hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>1000 milligrams by mouth (PO) Every 12 Hours</description>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>0.25 micrograms PO Every 12 Hours</description>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are scheduled for total thyroidectomy, and/or extensive neck dissections
             (pharyngectomy, laryngectomy, unilateral/bilateral/central neck, and/or mediastinal
             lymph node neck dissections).

          2. Patients who develop, between 18-24 hours after surgery, hypocalcemia as defined by a
             corrected serum calcium &lt;8.0mg/dL. [Corrected serum calcium (mg/dL) = Measured calcium
             + (4-albumin) x 0.8]

        Exclusion Criteria:

          1. Patients who have jejunal tubes

          2. Patients &lt;18 years old.

          3. Treatment with teriparatide or calcitriol (Rocaltrol) within 1 month prior to surgery

          4. Treatment with a bisphosphonate within 3 months prior to surgery

          5. Hypercalcemia (corrected serum calcium &gt;10.5mg/dL) or hypocalcemia (corrected serum
             calcium &lt;8.4mg/dL) on preoperative labs (drawn within 21 days of surgery)

          6. Paget's disease of bone

          7. Elevated alkaline phosphatase &gt; institutional upper limit of normal (ULN)

          8. History of external beam irradiation to the skeleton

          9. History of skeletal metastases

         10. History of untreated gout

         11. History of unstable angina pectoris

         12. History of symptomatic orthostatic hypotension

         13. Pregnancy (as screened by a serum/urine pregnancy test) or breast-feeding. Female
             subjects of childbearing potential must have a negative pregnancy test within 7 days
             of surgery. Postmenopausal women (absence of menses for 12 months) or women with
             history of hysterectomy or bilateral oophorectomy will not be required to have a
             pregnancy test. Male and female patients of reproductive potential must agree to
             utilize an effective form of contraception throughout the study period. The definition
             of effective contraception will be based on the judgment of the Investigator or
             designated associate.

         14. Hepatic and renal dysfunction defined by the following parameters: (a) Serum AST
             (SGOT) and ALT (SGPT) &gt; 3 times the institutional ULN, (b) Total serum bilirubin &gt; 2
             times the institutional ULN, (c) Serum creatinine &gt; 1.5mg/dL or estimated creatinine
             clearance &lt; 40mL/min

         15. Psychiatric illness or social situation that would limit compliance with study
             requirements

         16. Concomitant use of digoxin

         17. Patients may not be receiving any other investigational agents or have participated in
             any investigational drug study within 28 days preceding the start of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mimi Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>August 13, 2010</results_first_submitted>
  <results_first_submitted_qc>August 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2010</results_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypocalcemia</keyword>
  <keyword>Teriparatide</keyword>
  <keyword>Forteo</keyword>
  <keyword>Calcium</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>Rocaltrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypocalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 2, 2008 to April 13, 2009. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>A total of 7 patients were consented and screened. None of the patients met study entry criteria and thus were not randomized to treatment. Due to slow accrual, the study was closed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Success</title>
        <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
        <time_frame>2 - 7 days post-treatment</time_frame>
        <population>Terminated due low accrual, none of 7 participants met eligibility criteria therefore not treated nor randomized to study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium + Calcitriol</title>
            <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Teriparatide 20 Mcg</title>
            <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide 40 Mcg</title>
            <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O4">
            <title>Teriparatide 60 Mcg</title>
            <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Success</title>
          <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
          <population>Terminated due low accrual, none of 7 participants met eligibility criteria therefore not treated nor randomized to study arms.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period 1 Year</time_frame>
      <desc>As no patient received study treatment, neither adverse events nor serious adverse events have occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mimi Hu, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

